Innova Captab Ltd

Q1 FY27Pharmaceuticals & Biotechnology

Innova Captab Ltd Q1 FY27 Results & Concall Highlights: Revenue, Margins & Order Book

Q1 FY27 earnings call: what management guided on revenue, margins and order book.

Price₹1,189

Market cap₹6.7K Cr

P/E43.7

Published9 Sept 2026

What the Q1 FY27 call signalled

4 of 4 strong

RevenueRank 2

MarginRank 2

CapexYes

Order bookYes

Not discussed on this call: fundraise.

The short version

Innova Captab expects to deliver over 20% volume growth year-on-year, maintaining this growth trajectory in upcoming quarters. The company expects to maintain **20%+ volume growth** in the coming periods, with an overall sales growth target of 20%+ for FY27.

From Innova Captab Ltd's Q1 FY27 earnings-call transcript · updated 9 Sept 2026.

Revenue & Sales Performance

Rank 2

Innova Captab expects to deliver over 20% volume growth year-on-year, maintaining this growth trajectory in upcoming quarters.
The guidance is approximately 20%+ volume growth for the full fiscal year FY27.
Growth is driven by ramp-up at the Jammu plant, expanding product portfolio, onboarding new customers and geographies, and deeper engagement with existing customers.
The Jammu facility, currently at 25-30% utilization, is projected to ramp up steadily, aiming to cross INR1,000 crores revenue.
The company aims for 20%+ sales growth, combining volume growth and favorable pricing/product mix.
Growth capex for FY27 and FY28 is expected around INR20-30 crores annually, mainly in capability augmentation and debottlenecking; greenfield expansions will be communicated separately.
The company also plans to expand into new dosage forms and therapeutic categories to sustain growth.

Profitability & Margins

The company expects to maintain **20%+ volume growth** in the coming periods, with an overall sales growth target of 20%+ for FY27.
EBITDA margin guidance is maintained at a **normalized 15% to 16% range, plus-minus 2%**, with potential improvement towards 17%-18% as Jammu plant ramps up.
Jammu plant has reported a **positive EBITDA margin** this quarter and is expected to contribute to margin expansion as it scales.
The company anticipates stable gross margins around **35.5% plus-minus 2%** for the full year.
Future margin improvement may be limited due to ongoing growth capex, but margins could inch towards **18%** in the medium term.
Earnings growth is expected to **outpace revenue growth**, supported by operational efficiency and expanded product portfolio.
The company will continue investing in capacity expansion and new categories to sustain growth trajectories.

See what Innova Captab Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

Yes

**Annual Capex Guidance for FY27 and FY28**:
- Maintenance capex: INR 20-25 crores annually.
- Growth capex (existing capability augmentation/de-bottlenecking): INR 20-30 crores annually.
**Nature of Growth Capex**:
- Mainly focused on internal debottlenecking, equipment replacement, and capacity doubling within existing plants.
**Greenfield/Big Expansion Projects**:
- Any future large greenfield or new category expansion will be communicated to the market.
- Current large capex like Jammu (around INR 500 crores) already done; future expansions expected to be in smaller tranches (~INR 200-250 crores).
**Baddi Plant Capex Update**:
- New plot acquisition done; plans are in progress and will be firmed up before public disclosure.
**Strategic Moves**:
- Any strategic/concurrent moves will have board approval and will be disclosed accordingly.

Fundraising & Capital Structure

No specific mention of any immediate new fundraising through debt or equity was made during the call.
The management indicated that any strategic concurrent moves, including major expansions or new greenfield projects, will be undertaken only with Board approval.
They affirmed that whenever a larger greenfield project or a significant new category expansion is planned, the company will inform the market with detailed proposals.
Current capex guidance is focused mainly on maintenance and internal capability augmentation, with growth capex in the range of INR20-30 crores annually.
No current plans or announcements for large-scale fundraising were disclosed in this call.

See what Innova Captab Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

Yes

Based on the transcript provided (pages 1-16 of Innova Captab Limited Q1 FY27 Earnings Call): - Specific details on the current or expected order book or pending orders were not explicitly mentioned in the available transcripts. - The management referred to healthy visibility of new products and geographies contributing to growth. - Jammu plant ramp-up and onboarding of new customers, products, and country approvals are underway, implying a growing order pipeline. - The company is confident of achieving 20%+ volume growth backed by steady ramp-up in Jammu and existing facilities. - No concrete figures on order book size or pending orders disclosed; focus is on capacity utilization, product approvals, and volume growth guidance. If more detailed order book data is needed, it may be outside the scope of the provided transcript.

How does Innova Captab Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

ThisInnova Captab Ltd

Rev 2Mar 2

See where Innova Captab Ltd sits in Pharmaceuticals & BiotechnologySee which companies these are, and every other name in the sector.Open rankings

Innova Captab Ltd — Quarterly revenue & net profit

Revenue Net profit

Dec 2024

Mar 2025

Jun 2025

Sep 2025

Dec 2025

Mar 2026

Reported quarterly figures (₹ Cr). Latest: revenue ₹448 Cr, net profit ₹38 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

What Innova Captab's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

IOL Chemicals (Q1 FY27)
Expansion plans supported by capex of INR 200-250 crores annually, with 60% towards expansion/new products and 40% towards efficiency improvements. Key concall…
Glenmark Pharma. (Q1 FY27)
Chronic respiratory segment in India showing over 25% growth; oncology and cardiovascular segments also strong. Key concall takeaways from Glenmark…
Strides Pharma (Q1 FY27)
markets continue to be broad-based growth drivers, with 17% YoY growth and expansion in B2B and B2C markets including Europe, UK, Nordics, Africa, LATAM, MENA…
Ind-Swift Labs. (Q1 FY27)
Capex of ₹250 crore planned over 2-2.5 years to enhance capacity and build warehouse, supporting growth (Page 14). Key concall takeaways from Ind-Swift…

Compare:vs Sun Pharmaceutical Industries Ltd vs Divi's Lab.vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were Innova Captab Ltd Q1 FY27 results?

What is Innova Captab Ltd share price analysis?

Innova Captab Ltd currently shows a moderate growth signal based on ranking data. The stock trades at a P/E of 43.7 with a market cap of ₹6,726 Cr. Investors should review the full earnings analysis for detailed insights.

Is Innova Captab Ltd planning capital expenditure?

Annual Capex Guidance for FY27 and FY28**: - Maintenance capex: INR 20-25 crores annually.

Keep Innova Captab Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.